Related Experiment Videos
Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor
S M Manders1, J R Kostman, L Mendez
1Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, USA.
Journal of the American Academy of Dermatology
|August 1, 1995
Summary
For severe aphthae unresponsive to standard treatments, granulocyte colony-stimulating factor (G-CSF) offers a novel therapeutic option. This case study highlights G-CSF
Area of Science:
- Immunology
- Infectious Diseases
- Gastroenterology
Background:
- Recalcitrant aphthae, particularly in HIV-infected individuals, pose significant treatment challenges.
- Standard therapies like corticosteroids, cyclosporine, and thalidomide may be ineffective in severe cases.
Observation:
- A patient with HIV and extensive aphthae showed no improvement with corticosteroids, cyclosporine, and thalidomide.
- The patient also developed severe colonic aphthae, indicating a complex and refractory condition.
Findings:
- Treatment with granulocyte colony-stimulating factor (G-CSF) resulted in rapid and sustained resolution of both oral and colonic aphthae.
- This represents a previously unreported therapeutic approach for severe, treatment-resistant aphthous stomatitis.
Implications:
- Granulocyte colony-stimulating factor (G-CSF) may be a viable alternative for managing refractory aphthous ulcers, especially in immunocompromised patients.
- Further research is warranted to explore the efficacy and safety of G-CSF in a broader patient population with severe aphthae.